Trial Profile
A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have Received at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated Disease Progression on the Last Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2023
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 13 Dec 2022 Results of sub analysis assessing safety and survival outcomes in patients exposed to all 3 classes of drugs and those not exposed to daratumumab, presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 21 Oct 2022 Last checked against ClinicalTrials.gov record.
- 18 Oct 2022 According to ClinicalTrials.gov record, protocol has been amended as change in timeframe for primary end point from 5 years to 3 years.